Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here ...

Keith Speights has positions in Amazon, Enbridge, Meta Platforms, and Vertex Pharmaceuticals. The Motley Fool has positions ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle ...

VIENNA — Tirzepatide was associated with improvements in body weight and body composition, and with lower insulin doses, in ...

Jon Peddie traces the evolution of GPUs from fixed-function pipelines to today’s AI-era shader monsters and shows how the ...

Boston Celtics star Jayson Tatum was forced to accept some harsh new realities — both on and off the court — after rupturing ...

Exagamglogene autotemcel (exa-cel), a CRISPR/Cas9 gene-edited cell therapy, eliminated vaso-occlusive crises in 97% of ...

Progress in the healthcare field is allowing us to live longer. However, as people age, their need for medical services tends to increase. Over the next few decades, the percentage of the world's ...

Learn more about whether Sapiens International Corporation N.V. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

CASGEVY is the first, and only, gene editing therapy approved for the treatment of transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD) in Europe - - Italy has the largest ...

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.